Edition:
India

Alembic Pharmaceuticals Ltd (ALEM.NS)

ALEM.NS on National Stock Exchange of India

515.60INR
22 Jun 2018
Change (% chg)

Rs-6.35 (-1.22%)
Prev Close
Rs521.95
Open
Rs516.85
Day's High
Rs532.00
Day's Low
Rs510.15
Volume
189,651
Avg. Vol
107,597
52-wk High
Rs589.40
52-wk Low
Rs414.40

Chart for

About

Alembic Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged developing formulations and active pharmaceutical ingredients (API). The Company focuses on anti-infective, analgesic and, cough and cold therapies. It also focuses on therapies, such as cardiology, diabetes, gynecology, gastrointestinal,... (more)

Overall

Beta: 0.37
Market Cap(Mil.): Rs94,710.40
Shares Outstanding(Mil.): 188.52
Dividend: 4.00
Yield (%): 0.80

Financials

  ALEM.NS Industry Sector
P/E (TTM): 25.87 30.95 32.74
EPS (TTM): 19.42 -- --
ROI: -- 14.84 14.38
ROE: -- 16.34 16.08

BRIEF-Alembic Pharmaceuticals March-Qtr Net Profit Rises

* MARCH QUARTER CONSOL NET PROFIT 937.9 MILLION RUPEES VERSUS PROFIT 930.4 MILLION RUPEES YEAR AGO

16 May 2018

BRIEF-Alembic Pharmaceuticals' Panelav Unit Gets Zero 483 Observations From U.S. FDA

* THERE WERE ZERO 483 OBSERVATIONS AT THE FACILITY Source text - https://bit.ly/2Hl7Sul Further company coverage:

24 Apr 2018

BRIEF-Alembic Pharmaceuticals Gets U.S. FDA Nod For Acyclovir Ointment USP, 5 Pct

* SAYS CO RECEIVED U.S. FDA APPROVAL FOR ACYCLOVIR OINTMENT USP, 5 PERCENT Source text - http://bit.ly/2qiUKur Further company coverage:

09 Apr 2018

BRIEF-Alembic Pharmaceuticals Says U.S FDA Issued 3 Observations For Panelav Formulation Facility

* SAYS U.S FDA CONDUCTED INSPECTION AT FORMULATION FACILITY AT PANELAV FROM 12 MARCH, 2018 TO 20 MARCH, 2018

21 Mar 2018

BRIEF-India's Alembic Pharmaceuticals Dec Qtr Consol PAT Rises

* DEC QUARTER CONSOL NET PAT 1.31 BILLION RUPEES VERSUS 843.9 MILLION RUPEES YEAR AGO

31 Jan 2018

BRIEF-Alembic Pharmaceuticals Says U.S. FDA Grants Orphan-Drug Designation To Rhizen Pharmaceuticals

* U.S. FDA GRANTS ORPHAN-DRUG DESIGNATION FOR TENALISIB TO RHIZEN PHARMACEUTICALS S.A. (RHIZEN) Source text - http://bit.ly/2C7DIYd Further company coverage:

26 Dec 2017

Earnings vs. Estimates